Korro Bio doses first cohort in Phase 1/2 trial of KRRO-121 for urea cycle disorders

Korro Bio dosed the first cohort of patients in its Phase 1/2 ANCHOR clinical study of KRRO-121, a subcutaneous RNA-editing oligonucleotide being tested to treat hyperammonemia in patients with urea cycle disorders and hepatic encephalopathy.

Detected & updated continuously · Source: Nebula